PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lam, Wing ^a   Jiang, Zaoli ^a   Guan, Fulan ^a   Huang, Xiu ^a   Hu, Rong ^a   Wang, Jing ^a   Bussom, Scott ^a   Liu, Shwu Huey ^b   Zhao, Hongyu ^a   Yen, Yun ^c   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PhytoCeutica Inc   (United States)

^c PhytoCeutica Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBANILAMIDE DERIVATIVE; HERBACEOUS AGENT; NICOTINAMIDE; PHY 906; PLANT EXTRACT; SCUTELLARIA BAICALENSIS EXTRACT; SORAFENIB;

ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMISTRY; CHINESE MEDICINE; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; LIVER NEOPLASMS; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; HUMANS; LIVER NEOPLASMS; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, NUDE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PLANT EXTRACTS; TUMOR MICROENVIRONMENT;

EID: 84925866848     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09384     Document Type: Article

References (33)

1. El-Serag, H. B. Hepatocellular carcinoma. N Engl J Med 365, 1118-1127 (2011).
2. Llovet, J. M. & Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327 (2008).
3. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-7109 (2004).
4. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390 (2008).
5. Tilton, R. et al. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chinese medicine 5, 30 (2010).
6. Lam, W. et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Science translational medicine 2, 45ra59 (2010).
7. Rockwell, S. et al. Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy. International journal of radiation biology 89, 16-25 (2013).
8. Wang, E. et al. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC medical genomics 4, 38 (2011).
9. Farrell, M. P. & Kummar, S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2, 253-256 (2003).
10. Kummar, S. et al. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 10, 85-96 (2011).
11. Saif, M. W. et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 17, 161-169 (2010).
12. Saif, M. W. et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 73, 373-380 (2013).
13. Yen, Y. et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer research 29, 4083-4092 (2009).
14. Talmadge, J. E., Donkor, M. & Scholar, E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer metastasis reviews 26, 373-400 (2007).
15. Shang, L. et al. Nutrient starvation elicits an acute autophagic response mediated by Ulk1 dephosphorylation and its subsequent dissociation from AMPK. Proc Natl Acad Sci U S A 108, 4788-4793 (2011).
16. Egan, D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456-461 (2011).
17. Abou-Alfa, G. K. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24, 4293-4300 (2006).
18. Zhang, Z., Zhou, X., Shen, H., Wang, D. & Wang, Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC medicine 7, 41 (2009).
19. Liu, S. H. & Cheng, Y. C. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. Journal of ethnopharmacology 140, 614-623 (2012).
20. Park, M. A. et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Molecular cancer therapeutics 9, 2220-2231 (2010).
21. Walker, T. et al. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol 76, 342-355 (2009).
22. Zhang, W. et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). Journal of chromatography. A 1217, 5785-5793 (2010).
23. Boya, P., Reggiori, F. & Codogno, P. Emerging regulation and functions of autophagy. Nat Cell Biol 15, 713-720 (2013).
24. Loos, B., Engelbrecht, A. M., Lockshin, R. A., Klionsky, D. J. & Zakeri, Z. The variability of autophagy and cell death susceptibility: Unanswered questions. Autophagy 9 (2013).
25. Tai, W. T. et al. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell death & disease 4, e485 (2013).
26. Patterson, K. I., Brummer, T., O'Brien, P. M. & Daly, R. J. Dual-specificity phosphatases: critical regulators with diverse cellular targets. The Biochemical journal 418, 475-489 (2009).
27. Cagnol, S. & Chambard, J. C. ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. The FEBS journal 277, 2-21 (2010).
28. Tewari, R., Sharma, V., Koul, N. & Sen, E. Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation. Journal of neurochemistry 107, 616-627 (2008).
29. Goillot, E. et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A 94, 3302-3307 (1997).
30. Cagnol, S., Van Obberghen-Schilling, E. & Chambard, J. C. Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death. Apoptosis: an international journal on programmed cell death 11, 337-346 (2006).
31. Cheng, Y., Qiu, F., Tashiro, S., Onodera, S. & Ikejima, T. ERK and JNK mediate TNFalpha-induced p53 activation in apoptotic and autophagic L929 cell death. Biochemical and biophysical research communications 376, 483-488 (2008).
32. An, H. J. et al. Activation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced cell death. The Journal of biological chemistry 281, 33939-33948 (2006).
33. Ogier-Denis, E., Pattingre, S., El Benna, J. & Codogno, P. Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. The Journal of biological chemistry 275, 39090-39095 (2000).